Bioretec Oy
OMXH:BRETEC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioretec Oy
Net Change in Cash
Bioretec Oy
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Net Change in Cash
-€2.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Net Change in Cash
€5.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
3%
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Net Change in Cash
-€7.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Net Change in Cash
-€558k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Net Change in Cash
-€1.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
13%
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Net Change in Cash
-€208k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Bioretec Oy
Glance View
Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.
See Also
What is Bioretec Oy's Net Change in Cash?
Net Change in Cash
-2.2m
EUR
Based on the financial report for Dec 31, 2025, Bioretec Oy's Net Change in Cash amounts to -2.2m EUR.
What is Bioretec Oy's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
26%
Over the last year, the Net Change in Cash growth was -248%. The average annual Net Change in Cash growth rates for Bioretec Oy have been 26% over the past three years .
